4:10 pm Achillion Pharma advances ACH-3422, Uridine-Analog Nucleotide Inhibitor, into clinical trial; initiates Phase 2 pilot study with ACH-3102, NS5A Inhibitor, for HCV
moreView todays social media effects on ACHNView the latest stocks trending across Twitter. Click to view dashboardSee who Achillion is hiring next, click here to view […]